ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR RESPIRATORY INFECTIONS IN COMMUNITY SETTINGS (TREATRESP)
- Registry ID
- TREATRESP
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- UNITY HEALTH TORONTO
- Start date
- 2026-04-28
- Last update
- 2025-02-25
Conditions
- INFLUENZA
- CORONAVIRUS DISEASE (COVID-19)
Related clinical trials
- A RANDOMIZED, OBSERVER-BLIND, ADAPTIVE, ACTIVE COMPARATOR-CONTROLLED, DOSE-RANGING, MULTICENTER, SAFETY, TOLERABILITY, AND IMMUNOGENICITY PHASE 1/2 STUDY OF A PLANT-BASED SEASONAL RECOMBINANT TRIVALENT VLP INFLUENZA VACCINE IN ADULTS 18 YEARS OF AGE
- A CONTROLLED HUMAN INFECTION MODEL FOR INFLUENZA: A PHASE 1 TRIAL TARGETING A/H3N2 STRAIN AS A FOUNDATION FOR PANDEMIC PREPAREDNESS
- PANDEMIC INFLUENZA VACCINE IN ORGAN TRANSPLANTATION (PIVOT TRIAL: SAFETY AND IMMUNOGENICITY OF PANDEMIC INFLUENZA VACCINE IN KDNEY TRANSPLANT RECIPIENTS
- AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND,
2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR
COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC
ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT
HIGH RISK OF PROGRESSING TO SEVERE ILLNESS
- PHASE 1/2 STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A PROPHYLACTIC PLASMID DNA BOOSTER VACCINE AGAINST SARS-COV- -002] IN GENERALLY HEALTHY ADULTS 18 YEARS AND OLDER
- A PHASE 2 TRIAL TO EVALUATE SAFETY AND IMMUNOGENICITY OF A NEXT-GENERATION
COVID-19 VACCINE DELIVERED BY INHALED AEROSOL TO HUMANS
View on source registry